Skip to main content
OpenTrials
Completed

NCT Number: NCT06193746

Laser Efficiency on Metabolic Parameters

Non-invasive laser therapy is laser blood irradiation improves many metabolic parameters. So, this study aims to assess the impact of Non-invasive laser therapy on lipid metabolism and renal out comes

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

45 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Toka

Cairo, Egypt

About this study

The metabolic syndrome is a constellation of interrelated metabolic risk factors especially central obesity, dyslipidemia, hyperglycemia, which all affect worse their kidney function, and all of this causing mortality. This time line requires a quick procedure that will enable us to implement safe and non-invasive therapeutic instruments adjacent therapy for metabolic syndrome cases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patients have Metabolic syndrome, started more than one year ago.
  • BMI ranged 30- 35Kg/m2.
  • They are on medical therapy for more than one year.
  • Clinically stable.

Exclusion criteria

  • taking specific drugs uncontrolled diseases
  • cardiovascular instability
  • sever e autonomic neuropathy
  • infection wound,
  • burn, allergy or another external injury
  • hypothyroidism
  • hemorrhagic disorders
  • history of cancer
  • pregnant women,
  • mental illness as schizophrenia or dementia.

Treatment and study plan

non-invasive laser therapy

Device

(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement

Other names: laser watch

Primary outcomes

  1. lipid profile change

    Time frame: 12 weeks following end of treatment

    laboratorial measurement of lipid in one mg/dl of blood

  2. glomerular function range change

    Time frame: 12 weeks following end of treatment

    laboratorial measurement of glomerular function range in one ml of blood/1minute/1.73m2

  3. creatinine change

    Time frame: 12 weeks following end of treatment

    laboratorial measurement of creatinine one mg/DL of blood

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Effect of Non-invasive on Lipid Metabolism and Renal Out Comes in Metabolic Syndrome

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jan 5, 2024
Registry last updated
Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.